New hemoglobin monitoring system for anemia screening introduced by OrSense Ltd.

Jul 9 2012

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced today at the 32nd International Congress of the International Society of Blood Transfusion (ISBT), in Cancun, Mexico, Glasswing^TM, its next-generation, wireless, non-invasive hemoglobin (Hb) measurement system for anemia monitoring, hemorrhage detection and pre-donation screening.

Hemoglobin (Hb) measurements allow the detection of anemia and hemorrhage, and are widely used in hospital wards such as operation rooms, ICU, ER and delivery rooms. In blood donation centers, a pre-donation Hb measurement of blood donors is required by most countries to protect anemic donors, and to ensure adequate Hb content of blood units. The determination of Hb levels of prospective blood donors is usually performed using capillary blood obtained by finger pricking, rendering current Hb screening methods invasive, painful, time consuming and labor intensive.

Glasswing, OrSense's next-generation, wireless device offers a unique, breakthrough non-invasive solution for accurate continuous and spot Hb measurements. The new portable, wireless system enables on-line storage and download of data, real-time communication with electronic medical records in the hospital or blood donation centers as well as with other digital data devices and printers. The device is well suited for use in a variety of clinical environments, including perioperative and critical care, emergency medicine, blood donation facilities, women’s health, primary care physician’s office and homecare.

"We are proud to introduce Glasswing, our improved revolutionary solution for non-invasive measurements of hemoglobin," said Lior D. Ma'ayan, CEO of OrSense. "OrSense's non-invasive solution improves anemia screening and monitoring by eliminating pain, reducing infection risk and enabling a simple and fast diagnosis. Hemoglobin measurements obtained by our system in multiple applications, showed accurate performance compared with the gold standard invasive reference values. Our non-invasive system was found to be environmentally friendly, safe, fast and easy to use by the operating staff, and is already in use in multiple blood donation centers and blood banks in around the world, improving donor and patient safety and care."

In addition, 2 poster presentations will be presented at ISBT, with results of clinical trials showing that Hb measurements obtained with OrSense's systems showed accurate performance compared with invasive point of care (POC) devices. Dr. M. Gavalaki of the Blood Transfusion Center at Laiko General Hospital, Athens, Greece will present a poster titled Evaluation of non-invasive pre-donation hemoglobin screening; and Aharon Weinstein, Vice President of Research at OrSense will present a poster titled Non-invasive hemoglobin sensor performance in anemia screening.

For additional information, please visit OrSense's new corporate website at www.orsense.com.

Non Invasive Hemoglobin Measurement

OrSense’s non-invasive Hb measurement has many advantages including the prevention of pain and potential transmission of infectious diseases, a reduced need for trained personnel, short measurement time, and the absence of bio-hazardous waste. Glasswing offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. This portable, wireless device operates via rechargeable batteries using a ring-shaped sensor that is fitted on the donor's finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This technology, called SpectOLight™, provides a quick, accurate and painless measurement of the donor's blood constituents, while greatly improving donors' comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

About OrSense

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 55 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company's FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. The Company's CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s website at www.orsense.com.